570 related articles for article (PubMed ID: 31818814)
1. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
2. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Merli M; Rossotti R; Travi G; Ferla F; Lauterio A; Angelini Zucchetti T; Alcantarini C; Bargiacchi O; De Carlis L; Puoti M
Transpl Infect Dis; 2019 Dec; 21(6):e13165. PubMed ID: 31487082
[TBL] [Abstract][Full Text] [Related]
4. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
Pham LV; Pedersen MS; Fahnøe U; Fernandez-Antunez C; Humes D; Schønning K; Ramirez S; Bukh J
Gut; 2022 Mar; 71(3):627-642. PubMed ID: 33833066
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR
Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140
[TBL] [Abstract][Full Text] [Related]
6. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
[TBL] [Abstract][Full Text] [Related]
9. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
10. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
11. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure with DAA therapy: Importance of resistance.
Sarrazin C
J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
[TBL] [Abstract][Full Text] [Related]
13. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Garcia-Cehic D; Rando A; Rodriguez-Frias F; Gregori J; Costa JG; Carrión JA; Macenlle R; Pamplona J; Castro-Iglesias A; Cañizares A; Tabernero D; Campos C; Buti M; Esteban JI; Quer J
J Viral Hepat; 2021 Sep; 28(9):1319-1324. PubMed ID: 33720484
[TBL] [Abstract][Full Text] [Related]
14. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR
J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351
[TBL] [Abstract][Full Text] [Related]
15. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
16. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
[TBL] [Abstract][Full Text] [Related]
17. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A; Dietz J; di Maio VC; Vermehren J; Paolucci S; Müllhaupt B; Coppola N; Cabezas J; Stauber RE; Puoti M; Arenas Ruiz Tapiador JI; Graf C; Aragri M; Jimenez M; Callegaro A; Pascasio Acevedo JM; Macias Rodriguez MA; Rosales Zabal JM; Micheli V; Garcia Del Toro M; Téllez F; García F; Sarrazin C; Ceccherini-Silberstein F;
J Antimicrob Chemother; 2020 Nov; 75(11):3349-3358. PubMed ID: 32772078
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]